A randomized trial and a real-world study can both inform weight-management care while answering different questions. The trial controls assignment to treatment. A routine-data study observes what happens within a healthcare system. Neither label, by itself, tells a reader everything about the quality or relevance of the evidence.
The most useful comparison asks how participants received treatment, what data were collected, which outcome was measured and how bias was addressed. It also avoids a false binary: a study can randomize treatment within routine care and use real-world data. The source of data and the design of treatment assignment are related but separate dimensions.
Randomization strengthens causal comparison
Random assignment aims to make treatment groups comparable at baseline, including factors researchers have not measured. When it is implemented well, it helps isolate the effect of the assigned intervention. Blinding, outcome measurement, follow-up and analysis still matter; randomization does not repair every later problem.
CONSORT 2025 emphasizes complete reporting of trial methods and results so readers can appraise those features. A trial described as randomized should show how assignment worked, who was included and what happened after enrollment. A flow diagram can reveal missing follow-up or unequal discontinuation that a headline leaves out.
In obesity treatment, the regimen also matters. Dose escalation, background counseling, access and monitoring may be more structured than in routine care. A strong causal finding for that setting can still leave questions about how the medicine will perform under different practical conditions.
Real-world data describe a setting, not one study design
FDA defines real-world data through information routinely collected about health and healthcare delivery, such as records and claims. Real-world evidence is the clinical evidence derived from analyzing those data. Observational studies are common uses, but routine data can also support randomized or pragmatic research.
A large database may offer long follow-up, diverse patients or outcomes uncommon in a smaller trial. It may also omit important details, record exposure imperfectly or measure outcomes only when someone returns for care. Size does not correct those problems automatically. Millions of records can produce a precise answer to a biased question.
A study’s relevance depends on whether its data are fit for the intended purpose. A prescription record does not necessarily prove that a person took the medicine. An absent weight measurement does not prove stable weight. The investigators need to explain how those uncertainties were handled.
Confounding is central to observational treatment comparisons
In routine care, people receiving different medicines may differ before treatment starts. Diagnosis, severity, insurance, clinician preference, prior treatment and ability to pay can influence selection. Those factors may also influence outcomes. That is the central confounding problem.
Matching and statistical adjustment can make measured characteristics more comparable. They cannot guarantee that every relevant difference was measured accurately. Residual confounding may remain even in a careful study. A reader should ask which variables were available and why the comparison group was chosen.
This does not make observational evidence useless. It makes design and sensitivity analyses important. A well-specified target question, appropriate active comparator, clear treatment start and checks under alternative assumptions can improve credibility. The conclusion should remain proportionate to what the design supports.
Two semaglutide–tirzepatide studies illustrate the difference
The 2024 JAMA Internal Medicine observational comparison studied adults receiving products labeled for type 2 diabetes in routine care. It used matched groups and an on-treatment approach, with observation ending for particular treatment changes or discontinuation. That provides useful information about a defined clinical setting, but it is not the same experiment as a randomized obesity-product comparison.
SURMOUNT-5 later randomized adults with obesity without type 2 diabetes to specified maximum-tolerated weekly regimens. It had a shared 72-week schedule and a direct assigned-treatment comparison. The studied populations, product context and approach to continuation differ from the observational study.
A result in the same direction can strengthen a broader understanding, but the numerical averages should not be treated as interchangeable confirmations of one universal effect. If results differ, first ask whether the studies estimated the same thing. Diabetes status, dose, follow-up, access and censoring may explain part of the difference without either study being fraudulent or irrelevant.
Treatment discontinuation can change who remains visible
An on-treatment analysis may stop observing a person’s treatment outcome when the medicine is discontinued. If discontinuation relates to poor response, symptoms or cost, the remaining group can become selected. The reason for leaving matters to interpretation.
A routine-data study may also lose measurements when someone changes provider, insurance or clinic. The result then reflects not only drug exposure but the system’s ability to continue observing people. This is different from a trial that actively follows participants after treatment ends, although trials can also have missing data.
Our estimand guide explains how handling such events changes the clinical question. The discontinuation guide separates tolerability, persistence and missing follow-up. Those concepts are useful in both randomized and observational research.
Everyday care is not one uniform population
A study from a specialty obesity clinic may offer intensive support and unusually good coverage. Another database may primarily capture people with diabetes or a particular insurance type. Calling both ‘real world’ does not make either automatically representative of every patient.
Read who could enter the study and who could remain observed. Geography, age, diagnosis, access and healthcare use can all affect applicability. A treatment study can be internally coherent while still having limited reach beyond its setting.
The same caution applies to trials. Strict entry criteria may exclude important groups, and volunteer participants may differ from people who do not enroll. The question is not whether one design owns reality. It is which part of reality the study describes and how confidently a comparison can be made within it.
Safety findings need their own scrutiny
Routine data can help investigate less common outcomes and longer exposure, but diagnostic coding and surveillance differences matter. People starting one treatment may be monitored more often and therefore have more events detected. An observed association should be examined for competing explanations.
Trials provide structured collection and randomized comparison, but may be too small or short for a rare long-term outcome. No observed event is not the same as zero risk. Different evidence sources may therefore complement each other, with neither settling the entire benefit-risk question alone.
Use the designs together without flattening them
For a treatment comparison, begin with the exact question and seek evidence that best addresses it. Randomized direct comparisons are especially valuable for causal efficacy questions. Routine-care studies can add information about persistence, access, populations and longer-term outcomes when designed appropriately.
The practical reading habit is consistent: identify population, assignment, exposure, endpoint, follow-up and analysis. Then state what remains uncertain. A design label is the start of appraisal, not its conclusion. Good evidence becomes more useful when the boundaries of its answer remain visible.
